A VISIONaerieĀ® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.
Learn MoreJoin us in creating the future of eye care!
Our Products
We currently market two innovative prescription eye drops for lowering intraocular pressure (IOP) in glaucoma.
Learn More
Our Research
We are making significant progress in developing new treatments for dry eye and retinal diseases.
Learn More
STOCK Quote
NASDAQ: AERI
$17.51USD
May 7, 4:00 PM ET
Latest News
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
DISCOVaerieā¢ Live!
Visit our virtual destination for the eye care community to get informed and connected.
MORE
CAREERS AT AERIE
We are looking for VISIONaerieSĀ® who share our passion for innovation to protect sight.
MORE
OUR ESG COMMITMENT
Aerie is dedicated to environmental stewardship, social responsibility, and good corporate governance.
MORE